Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: February-26-14
Credit Expiration Date: February-26-15

Faculty

Contributing Author:
Dr. Brian G. Feagan
Professor
University of Western Ontario
Director – Robarts Clinical Trials, Inc
London, Ontario, Canada

Series Chair:
Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
Philadelphia, PA

CCME Reviewer:
David A. Greenwald, MD
Professor of Clinical Medicine
Department of Medicine (Gastroenterology & Liver Diseases)
Montefiore Medical Center
Bronx, NY

Credit Hours

Physicians: 0.5 AMA PRA Category 1 CreditTM

Medium

i-Newsletter

Program Description

A CME-certified interactive newsletter series on the recognition, diagnosis, and treatment of ulcerative colitis (UC).


UC is a chronic condition with substantial morbidity, including debilitating symptoms, frequent need of high-risk procedures such as surgery, and decreased health-related quality of life. The medical management of UC has changed significantly in recent years due to progress in basic research that continues to provide new insight into the pathogenesis of UC. Four major classes of medical therapies are used for the treatment of UC: aminosalicylates (5-ASA), steroids, immune modifiers (azathioprine and 6-MP), and biologics (infliximab). In order for gastroenterologists to implement best practices when treating patients with UC, they must understand the risks and benefits of available treatment options and be able to develop tailored regimens based on unique patient and disease factors.

The goal of this continuing medical education activity is to increase the ability of gastroenterologists to integrate best practices based on the latest clinical evidence for the treatment of UC, ultimately improving quality of life and reducing complications for patients with inflammatory bowel disease (IBD).

Program Developer/Facilitator

This activity is jointly provided by Albert Einstein College of Medicine and Montefiore Medical Center, and MCM Education.

Target Audience

This activity is intended for gastroenterologists and other clinicians interested and involved in the evaluation, diagnosis, and management of patients with UC.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss current treatment algorithms for UC management.
  2. Describe data from clinical trials for emerging investigational agents for UC.

Disclosures

The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present. Albert Einstein College of Medicine and MCM Education staff have no conflicts of interest with commercial interests related directly or indirectly to this educational activity.

Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product not yet approved for use in the United States.

Dr. Feagan Disclosures:
Grant support from Abbott, ActoGeniX, Bristol-Myers Squibb, Centocor, CombinatoRx, Elan/Biogen, Genentech, Merck, Millennium, Novartis, Protein Design Labs, Tillotts, UCB, Wyeth
Consultant to AbbVie; Actogenix; Albiero Pharma; Amgen; AstraZeneca; Athersys; Avaxia Biologics, Inc; Axcan;Bioehringer Ingelheim France; Bristol-Myers Squibb; Celgene; Centocor; Elan/Biogen; Ferring Pharma A/S; Genentech; GiCare Pharma; Gilead; Given Imaging, Inc; GSK; Ironwood Pharma; J&J/Janssen; Merck; Millennium; Nektar; Novo Nordisk; Prometheus Therapeutics and Diagnostics; Pfizer; Salix Pharma; Serono; Shire; Sigmoid Pharma; Synergy Pharma, Inc; Takeda; Teva; Tillotts; UCB; Unity Pharmaceuticals; Wayner-Chilcott; Wyeth; Zealand Pharm; Zyngenia
Speakers bureau for Abbott, J&J/Janssen, UCB Pharma
Medical advisory board for Abbott; AstraZeneca; Celgene; Centorocr, Inc; Elan/Biogen; Merck; Novartis; Pfizer; Prometheus Laboratories; Slaix Pharma; Takeda; Tillotts Pharma AG; UCB Pharma

Dr. Lichtenstein Disclosures:
Grant support from Alaven; Bristol-Myers Squibb; Ferring; Janssen Orthobiotech; Prometheus Laboratories, Inc.; Salix; Shire; Takeda; UCB; Warner Chilcotte
Consultant to Abbott Corporation; Alaven,; Elan; Ferring; Janssen Orthobiotech; Hospira; Millenium; Ono; Pfizer; Prometheus Laboratories, Inc.; Salix; Santarus; Schering-Plough Corporation; Shire; Takeda; UCB; Warner Chilcotte.


The Staff of CCME of Albert Einstein College of Medicine have no disclosures to report with any commercial interests relative to this CME activity.
Dr. David Greenwald has no disclosures.

Lillian McVey, Medical Writer, has no disclosures.
Kathleen Hines, MCM Editorial Director, has no disclosures.

Credit Statements

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine, Montefiore Medical Center and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Albert Einstein College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit is awarded to participants who score 60% or better on the post-test.

This activity will take approximately 30 minutes to complete.

Commercial Support Statements

.

Instructions

There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; physicians should claim only those credits that reflect the time actually spent in the activity.

  1. Review the intended audience, learning objectives, and author disclosures.
  2. Study the educational content online. Be sure to review both written and audio/slide content.
  3. Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
  4. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Certificate Fee

$0.00

Disclaimer

Presented by Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, and MCM Education.

The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, Salix, Shire, or Takeda. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS